DS-3201b in Participants With Lymphomas

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1. 1Since this is a Phase 1 trial focused on finding the right dose of DS-3201b and tracking side effects, what does that mean for what's currently known — and not yet known — about its safety for someone with my type of lymphoma?
2. 2The trial is actively monitoring dose-limiting toxicities and treatment-emergent adverse events — what kinds of side effects have been seen so far in participants, and how would those be managed if they happened to me?
3. 3The trial is no longer recruiting new participants, so is there any chance I could still be considered for enrollment, or would it make more sense to look at other trials or standard treatments for my lymphoma right now?
4. 4I noticed the trial includes a drug-drug interaction cohort studying how DS-3201b interacts with other medications — would any medicines I currently take potentially be a concern if I were evaluated for a study like this?
5. 5Given that this is a Phase 1 study primarily designed to study dosing and pharmacokinetics rather than to prove the drug works, how would you weigh this against standard treatment options that already have more established evidence for my specific type of lymphoma?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.